Trial Profile
A placebo controlled, randomized study to examine the impact of 24-week orlistat treatment on postprandial triglyceridaemia, steatohepatitis and cardiovascular risk factors in overweight Chinese patie
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2012
Price :
$35
*
At a glance
- Drugs Orlistat (Primary)
- Indications Dyslipidaemias; Overweight
- Focus Pharmacodynamics
- Sponsors Roche
- 20 Apr 2012 New trial record